Decera Clinical Insights

We can’t wait to debut our new look at #ASH25 👀✨
Meet Decera Clinical Insights (formerly CCS + MDOutlook) in person.
Find us at Booth 142.
Learn more: https://bit.ly/48xYxKN

#ASH2025 #MedicalInsights #MedicalStrategy #DeceraClinical

We’re now Decera Clinical Insights (deh-SAIR-uh), formerly MDOutlook and CCS. Our name has evolved, but our trusted expertise, real-world data, and strategic intelligence remain the same. Thank you for celebrating this next chapter with us! Learn more: corporate.deceraclinical.com?utm_source=b...

BIG NEWS! Clinical Care Solutions (CCS) is evolving into Decera Clinical Insights (deh-SAIR-uh) — a new name built for the future. Our look is changing, but your experience will stay the same. The same expert team, trusted science, and meaningful insights — now under one unified brand.

🌍 In this Oncology Unscripted clip, Dr Marshall reflects on how shifting global regulatory landscapes may create opportunities to reduce drug development costs while keeping innovation at the forefront.

👉 Watch now: https://bit.ly/47vADio

#OncologyUnscripted #ESMO #Oncology #DrugDevelopment

In the latest episode of #OncologyUnscripted, Dr. Marshall sits down with Dr. Powles to explore how MRD-positive disease represents its own unique biology, and why traditional regimens like FOLFOX may not be the right answer in this setting.

🎥 Watch: https://bit.ly/46Z51la

“How do we treat smarter?” 💡 Dr Marshall sits down with genitourinary cancer expert Dr Thomas Powles to discuss how ctDNA and measurable residual disease (MRD) are reshaping patient selection for adjuvant therapy.

👉 Watch the full conversation: https://bit.ly/49aAeTV

New Episode of #OncologyUnscripted! Explores key updates #ESMO25:
🔹 Emerging trends in precision oncology
🔹 The growing role of ctDNA in treatment strategies
🔹 China’s expanding influence in clinical research and oncology treatment .

👉 Watch the full video here: https://bit.ly/47vADio

October is all about PINK & happy stories. 1/3 of #inflammatorybreastcancer pts are stage 4 at dx, 1/3 develop stage 4, remaining 1/3 are NED/no evidence of disease. Don't ignore stage 4....be there for those whose treatment goes on and on and on. They need your support & help. #stage4needsmore

Have you caught up on the latest episodes of #OncologyUnscripted? 🎙️ We release a new conversation every month, bringing you timely insights from leading experts on the evolving oncology landscape.

Watch right here: clinicalcaresolutions.net/content/dr-j...

In this moment, Dr. Marshall & Dr. Cannon dig into the why behind the link between ultramarathoners and higher rates of precancerous polyps. A closer look at how endurance training and lifestyle choices may unexpectedly influence cancer risk.
👉 Watch the full episode: https://bit.ly/4pzrfBz

“If enough of us get out and scream… if enough of us rise up—we can take back our healthcare and our successes, so we don’t step backwards.” – Dr. @marshalj23

Watch the latest episode here: https://bit.ly/4259gZG

#OncologyUnscripted #CancerCare #VaccineAccess #PublicHealth

🏃 Can too much exercise actually increase cancer risk? Dr. John Marshall sits down with Dr. Timothy Cannon to unpack surprising new data: ultramarathoners may face higher rates of precancerous polyps.
👉 Watch the full conversation: https://bit.ly/46f5yiA
#OncologyUnscripted #CancerCare #ColonCancer

Vaccine access is unraveling, and cancer patients may be the first to suffer. Dr. John Marshall sounds the alarm on:
✔️ CDC disruptions ✔️ Anti-vaccine rhetoric ✔️ Shifts in vaccine policy

👉 Watch Episode 21 now: https://bit.ly/4259gZG

Have you caught up on the latest episodes of #OncologyUnscripted? 🎙️ We release a new conversation every month, bringing you timely insights from leading experts on the evolving oncology landscape.

Watch the latest episodes with Dr. John Marshall right here: https://bit.ly/42bsFYQ

#OncologyUnscripted is now streaming as a podcast! 🎙️ Wherever you listen, you can now access in-depth discussions on the evolving oncology landscape.

👉 Listen on Spotify: https://bit.ly/4niGP2i
👉 Listen on Apple: https://apple.co/3K9vfbw

👀 More young, healthy adults—no family history, no genetic markers—are being diagnosed with colon cancer. Nearly 90% are rectosigmoid cases.

Why? The microbiome is one theory, but the cause remains unclear.

Watch #OncologyUnscripted with Dr. John Marshall: ▶️ https://bit.ly/3HMy0yQ

Younger patients with colon cancer often report every side effect, while older patients rarely mention them at all. Dr Marshall sits down with patient Chad Leo and Dr. Thejas Jayakrishnan to discuss the rise of early-onset GI cancers, treatment challenges: https://bit.ly/45IFGtN

Younger patients with GI cancers face a unique set of challenges. In this #OncologyUnscripted episode Dr. Marshall explores why early onset GI cancers are not just the same disease at a younger age and why the medical community needs to better understand & address this trend. https://bit.ly/4oOQuPV

Younger patients are being diagnosed with cancer at rising rates—especially GI cancers. In this #OncologyUnscripted episode, Dr John Marshall breaks down a new JAMA review on early-onset GI cancers.

▶️ Watch here: https://bit.ly/3HMy0yQ

100% benefit rate, but not 100% access.

In this episode of #OncologyUnscripted, Dr. John Marshall breaks down how smarter cancer care means not just new innovations, but affordable, accessible treatment for all. clinicalcaresolutions.net/activities/o...

Oncology Unscripted With John Marshall | CCS Oncology Unscripted with John Marshall, MD offers a unique take on the latest oncology news, including science, clinical research, and in-depth interviews relevant to clinical practice.

#OncologyUnscripted is designed to bring you a unique take on the latest oncology news including business news, gossip, science, and a special in-depth segment relevant to clinical practice. Check out our recent episodes here! clinicalcaresolutions.net/content/dr-j...

Pancreatic Cancer 2025: After More Than 30 Years, Is That Light on the Horizon? @marshalj23.bsky.social shares insights in the Spring Issue of Oncolytics Today. Read the full article, pages 77-79-https://www.ncoda.org/news/oncolytics-today-spring-2025/

We Funded the Cure—Now We're Pulling the Plug? Welcome to Washington DC. My name is John Marshall.

Dr. Marshall asks: How do we fight the dismantling of this important system and protect progress?

Read below or watch this episode here: lnkd.in/gjTraEmB

www.linkedin.com/pulse/we-fun...

In this powerful episode of From Lab Coats to Leadership, Dr. Marshall speaks with Dr. Lucile Adams-Campbell and two other trailblazing women in science about mentorship, representation, and the fight for equity in medicine. clinicalcaresolutions.net/content/dr-j...

From Science to Survival: Cancer Research in Crisis Dr Marshall highlights practice-changing research at ASCO GI, and discusses the turmoil caused by the new presidential administration’s abrupt policy changes.

.@marshalj23.bsky.social reflects on the emotional toll of ongoing uncertainty in healthcare, particularly the impact on both providers and patients in the latest episode of #OncologyUnscripted. @clinicalcaresol.bsky.social bit.ly/3DxloJF

New Treatments Give Hope to Patients With One of the Deadliest Cancers Half of all pancreatic-cancer patients live less than a year after diagnosis. But researchers say there is potential for change.

“Pancreatic cancer has been the graveyard for drug discovery,” said Benjamin Weinberg, MD, a gastrointestinal medical oncologist at @georgetownlombardi.bsky.social.

Researchers believe that could change with newer therapies, particularly those that target KRAS.

www.wsj.com/health/healt...

🎉 Subscribe to #OncologyUnscripted for:

✨ Groundbreaking science & industry updates
✨ Expert interviews reshaping clinical practice
✨ A unique blend of facts, fun, & insight you won’t find anywhere else

👉 Subscribe today bit.ly/41vFVWW

@clinicalcaresol.bsky.social

Learn to Identify Fatty Liver Disease In Primary Care Dr Mistry sits down with Dr Mary Rinella to discuss the most up-to-date strategies for early recognition of fatty liver disease in patients.

Did you know? Obesity, type 2 diabetes, and hypertension increase the risk of fatty liver disease, often with no early symptoms. Dr. Neeraj Mistry & Dr. Mary E. Rinella discuss key clues for early detection.

clinicalcaresolutions.net/activities/g...

Rebranding Fatty Liver Disease: What’s in a Name? In this episode of Unlocking the Fatty Liver Mistry, Dr Mistry explains the nomenclature change for fatty liver disease and why it matters.

Big change in fatty liver disease terminology! NAFLD & NASH are now MASLD & MASH, a shift to reduce stigma & improve accuracy. Language matters in healthcare! #MASH #LiverHealth clinicalcaresolutions.net/activities/g...

Our next episode of #OncologyUnscripted is dropping soon!

Trust us, you don’t want to miss this one...subscribe: pages.mycea.com/oncology-uns...